NSE ScannerHospitals & Diagnostics · Hospital/Nursing Management · NSE: INDRAMEDCO · data 2026-10-30
Indraprastha Medical Corporation Limited
In plain words
Price: 52.3% below its 52-week high of ₹640.85.
Delivery: 55.9% of traded shares were kept for delivery over the last 10 sessions, against 57.6% over the last 60.
Latest results: a net profit of ₹54 cr for the quarter ended Sept 2026 (+8.3% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹1,524 cr |
| Net profit (last 12 months) | ₹188 cr |
| Sales growth, 3 years (yearly) | 10.5% |
| Profit growth, 3 years (yearly) | 28.7% |
At a glance
Promoters 51.0% (unchanged in a year), pledged 0.0%, institutions 4.2%.
P/E 14.9, dividend yield 1.3%. Price relative to earnings and book value (low is cheaper, not better).
ROE 27.5%, ROCE 30.0%, operating margin 15.0%: how much profit it earns on the money it uses.
Debt/equity 0.05, Profit growth 28.7% and sales growth 10.5% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- High return on equity (27.5%).
- Profit grew 28.7% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q2 FY27)
INDRAMEDCO Q2 FY27 results (standalone figures, as filed on NSE).
Revenue was ₹412.85 crore, up 8.4% YoY and up 1.6% QoQ.
Net profit was ₹53.58 crore, up 8.3% YoY and down 4.1% QoQ.
Operating margin was 18.8% (18.7% a year ago).
EPS was ₹5.84, up 8.1% YoY and down 4.1% QoQ.
INDRAMEDCO के Q2 FY27 नतीजे (स्टैंडअलोन आंकड़े, NSE पर दाखिल)।
राजस्व: ₹412.85 करोड़; पिछले साल की तुलना में 8.4% की बढ़त, पिछली तिमाही की तुलना में 1.6% की बढ़त।
शुद्ध मुनाफ़ा: ₹53.58 करोड़; पिछले साल की तुलना में 8.3% की बढ़त, पिछली तिमाही की तुलना में 4.1% की गिरावट।
ऑपरेटिंग मार्जिन: 18.8% (एक साल पहले 18.7%)।
EPS: ₹5.84; पिछले साल की तुलना में 8.1% की बढ़त, पिछली तिमाही की तुलना में 4.1% की गिरावट।
INDRAMEDCOના Q2 FY27 પરિણામો (સ્ટેન્ડઅલોન આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹412.85 કરોડ; ગયા વર્ષની સરખામણીએ 8.4% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 1.6% વધારો.
ચોખ્ખો નફો: ₹53.58 કરોડ; ગયા વર્ષની સરખામણીએ 8.3% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 4.1% ઘટાડો.
ઓપરેટિંગ માર્જિન: 18.8% (એક વર્ષ પહેલાં 18.7%).
EPS: ₹5.84; ગયા વર્ષની સરખામણીએ 8.1% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 4.1% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
19/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 14/30: Delivery 63.8% over the last 20 sessions vs 34.4% in the 40 before (1.85x); shares delivered per day 0.78x usual; 1 delivery-spike day (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend
- 29 Oct 26Results Q2 FY27 results: profit +8.3% YoY -2.5% next session
- 18 Sept 26Dividend Dividend ₹4 (ex-date) +0.6% next session
- 6 Aug 26Results Q1 FY27 results: profit +8.5% YoY +3.4% next session
- 12 May 26Results Q4 FY26 results: profit +1.7% YoY -9.7% next session
- 3 Feb 26Results Q3 FY26 results: profit +25.0% YoY +3.0% next session
- 5 Nov 25Results Q2 FY26 results: profit +16.7% YoY +3.1% next session
- 18 Sept 25Dividend Dividend ₹4.5 (ex-date) -1.4% next session
- 6 Aug 25Results Q1 FY26 results: profit +14.9% YoY +3.2% next session
- 16 May 25Results Q4 FY25 results: profit +31.6% YoY +1.8% next session
- 3 Feb 25Results Q3 FY25 results: profit +11.4% YoY -6.6% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (standalone)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹413 cr | ₹54 cr | +8.3% | 18.8% | 5.84 |
| Jun 2026 | ₹406 cr | ₹56 cr | +8.5% | 19.7% | 6.09 |
| Mar 2026 | ₹365 cr | ₹42 cr | +1.7% | 16.6% | 4.55 |
| Dec 2025 | ₹372 cr | ₹41 cr | +25.0% | 16.7% | 4.47 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 51.00% | 51.00% | 51.00% | 51.00% |
| Foreign institutions (FII) | 2.39% | 2.77% | 2.44% | 2.73% |
| Domestic institutions (DII) | 1.77% | 0.59% | 0.88% | 0.83% |
| Mutual funds | 0.91% | 0.01% | 0.01% | 0.00% |
| Retail investors | 22.85% | 22.33% | 21.23% | 20.64% |
| Number of shareholders | 77,706 | 75,098 | 72,980 | 71,225 |
Common questions
What was Indraprastha Medical Corporation Limited's latest quarterly profit?
Indraprastha Medical Corporation Limited reported a net profit of ₹54 cr for the quarter ended Sept 2026 (+8.3% on the same quarter a year earlier), on revenue of ₹413 cr.
How much do promoters hold in Indraprastha Medical Corporation Limited?
Promoters held 51.00% of Indraprastha Medical Corporation Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Indraprastha Medical Corporation Limited debt-free?
Its latest reported debt-to-equity ratio is 0.05, which is very low.
What is Indraprastha Medical Corporation Limited's P/E ratio?
About 14.9, based on the last 12 months' earnings and a price of ₹305.65 (data 2026-10-30).
What is the 52-week high and low of Indraprastha Medical Corporation Limited?
The 52-week high is ₹640.85 and the 52-week low is ₹293.65.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Indraprastha Medical Corporation Limited | ₹305.65 | ₹2,910 cr | 14.9 | — | 27.5% | 30% | 0.05 | -46.9% |
| Kovai Medical Center & Hospital Ltd. | ₹5,816 | ₹6,356 cr | 25.2 | — | 20.3% | 20.6% | 0.31 | +131.5% |
| Artemis Medicare Services Ltd. | ₹293.2 | ₹4,626 cr | 39.8 | — | 11.7% | 12% | 0.28 | +19.2% |
| KMC Speciality Hospitals (India) Limited | ₹148.39 | ₹2,422 cr | 43.4 | — | 24.9% | 25.1% | 0.4 | +7.8% |
| Gujarat Kidney & Super Speciality Ltd. | ₹163.31 | ₹1,289 cr | 81.3 | — | 11.1% | 14.7% | 0.12 | +36.1% |
| Shalby Ltd. | ₹120.64 | ₹1,306 cr | 32.8 | — | 3.7% | 6% | 0.59 | -51.3% |
Compare INDRAMEDCO with KOVAI in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open INDRAMEDCO in NSE Scanner →